Stockscreener 앱 받기
1.63
2.52%
0.04
시간 외 거래:
1.65
0.02
+1.23%
전일 마감가:
$1.59
열려 있는:
$1.58
하루 거래량:
1.80M
Relative Volume:
1.58
시가총액:
$406.01M
수익:
$14.56M
순이익/손실:
$-63.37M
주가수익비율:
-5.857
EPS:
-0.2783
순현금흐름:
$-19.44M
1주 성능:
+5.84%
1개월 성능:
+1.24%
6개월 성능:
-9.94%
1년 성능:
+280.04%
1일 변동 폭
$1.58
$1.685
1주일 범위
$1.45
$1.685
52주 변동 폭
$0.40
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
명칭
Lineage Cell Therapeutics Inc
전화
510-871-4188
주소
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.63 | 396.05M | 14.56M | -63.37M | -19.44M | -0.2783 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Craig Hallum | Buy |
| 2022-11-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-14 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Noble Capital Markets | Outperform |
| 2021-03-31 | 개시 | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration - simplywall.st
Lineage Announces Formation of Scientific Advisory Board - BioSpace
Lineage Cell Therapeutics (LCTX) Establishes New Scientific Advi - GuruFocus
Lineage Cell Therapeutics forms advisory board, names clinical head By Investing.com - Investing.com Australia
Lineage Cell Therapeutics forms advisory board, names clinical head - Investing.com
Guidance Update: Can Lineage Cell Therapeutics Inc maintain sales growth2026 Market Trends & Reliable Intraday Trade Alerts - baoquankhu1.vn
Tech Rally: Is Lineage Cell Therapeutics Inc still a buy after recent gains2026 Stock Rankings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
If You Invested $1,000 in Lineage Cell The (LCTX) - Stock Titan
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - PR Newswire
Biotechs Racing to Translate Longevity Science Into Real TherapiesAnd One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - The Malaysian Reserve
Lineage Cell Therapeutics launches COR1 for corneal diseases amid rising FECD prevalence - Traders Union
Q4 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Pharma News: Can Lineage Cell Therapeutics Inc reach resistance levels soon2026 Technical Overview & AI Enhanced Trading Signals - baoquankhu1.vn
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines - Sahm
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
Lineage Cell Therapeutics (LCTX) price target increased by 20.00% to 5.10 - MSN
Q3 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Lineage Cell Therapeutics pushes scalable platforms to address drug discovery complexity - Traders Union
Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history - Yahoo Finance UK
Lineage Cell (LCTX) Launches Its Latest Cell Therapy Program - Yahoo Finance
Earnings Miss: What are the future prospects of Lineage Cell Therapeutics Inc2026 Trade Ideas & Long-Term Growth Stock Strategies - baoquankhu1.vn
Lineage Cell Therapeutics launches new CED cell therapy program - Eyes On Eyecare
10 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Volume Recap: Can Lineage Cell Therapeutics Inc maintain sales growthTrade Performance Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Retail Trends: Is now the right time to enter Lineage Cell Therapeutics IncGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Aug Breakouts: Is Lineage Cell Therapeutics Inc stock overvalued or fairly priced2026 Institutional Moves & Safe Entry Momentum Stock Tips - baoquankhu1.vn
LCTX Should I Buy - Intellectia AI
Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX - MarketBeat
B. Riley Financial Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - MarketBeat
ETF Watch: Is Lineage Cell Therapeutics Inc a top pick in the sector2026 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn
LCTX: HC Wainwright Reiterates Buy Rating with $9 Price Target | - GuruFocus
HC Wainwright Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease - BioSpace
Lineage Cell Therapeutics unveils preclinical therapy for Fuchs dystrophy and Bullous Keratopathy - Traders Union
Lineage Cell Therapeutics (LCTX) Expands with New Corneal Cell T - GuruFocus
[EFFECT] Lineage Cell Therapeutics, Inc. SEC Filing - Stock Titan
Geopolitics Watch: Can Lineage Cell Therapeutics Inc scale operations efficiently2026 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Insider Buying: Brian Culley Acquires 15,000 Shares of Lineage C - GuruFocus
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) CEO Brian Culley Purchases 15,000 Shares - MarketBeat
Lineage Cell Therapeutics (LCTX) CEO adds 15,000 shares in open-market purchase - Stock Titan
Lineage Therap Expands ATM Equity Offering Capacity - The Globe and Mail
Lineage Cell Therapeutics, Inc. Files Form 8-K for At-The-Market Offering – Key Company and Security Information (LCTX, NYSEAMER) 232425 - Minichart
Lineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programs - MSN
Lineage Cell Therapeutics files prospectus supplement for up to $60 million share offering - Investing.com
Lineage Cell Therapeutics files prospectus supplement for up to $60M ATM equity offering - TradingView
Lineage Cell Therapeutics Inc (LCTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):